|
|
Post by notamnkdmillionaire on Jun 7, 2014 9:50:11 GMT -5
|
|
|
|
Post by thekindaguyiyam on Jun 7, 2014 14:54:40 GMT -5
there is a lot of ignorance on the behalf of some doctors who apparently have a learning curve. My endocrinologist was thinking Exubra when I brought up Afrezza; I had to educate him. As the doctors who do not stay current and have established biases based on past inhalation performance it will be the patients who want to puff instead of inject followed by huge media attention. IMHO
|
|
|
|
Post by chmith27 on Jun 7, 2014 15:29:48 GMT -5
doctors aren't going to know anything about a drug that they can't prescribe, unless they are invested in the drug. our local endo doc had never heard of it a few months ago-that's normal. it's going to take an enormous marketing effort and a lot of patient chatter to get afrezza sold.
|
|
|
|
Post by ashiwi on Jun 7, 2014 15:40:34 GMT -5
As a Podiatrist I treat diabetics every day . I ask everyone what their treatment regimen is and how well it controls their glucose level. My unscientific survey has shown that there are a lot unhappy and not very well controlled diabetics out there. Of course I bring up Afrezza and it's benefits besides it's convenience of inhalation. They are all very interested and can't wait for it to be available. I tell them to ask their endo's and PCP's about it. I'm trying to start my own little sales force with a grass roots effort. Ultimately with the right marketing partner, I can't imagine how Afrezza won't be a huge success . Just a couple more hurdles>> FDA approval and partner deal inked. We'll have our answers within the next few weeks. (Al Mann's words)
|
|
|
|
Post by spiro on Jun 7, 2014 15:45:49 GMT -5
Good point thekindaguyiyam, a lot of doctors will soon be getting educated by their patients on Afrezza.
|
|
|
|
Post by kc on Jun 7, 2014 16:28:10 GMT -5
I have a friend who is a respected endocrinologist who evidently was involved with the Pfizer trial. When I sent him info on Mannkind last month he seemed disinterested which really surprised me. He indicated that market reacted poorly to the Pfizer bust and didn't know much about this one. Seemed that he didn't want to discuss it so I wondered if he was not in a position to discuss it. He has traveled and given presentations on diabetes and medications in the past and I wondered if perhaps he knew more than the could tell me. He was aware of who Alfred Mann was and all the past products he was involved in.
So perhaps he knows more or is just not interested because of his past involvement in the Pfizer trials.
I am am by the way bullish on Mankind.
|
|
|
|
Post by thekindaguyiyam on Jun 7, 2014 18:04:01 GMT -5
Good point thekindaguyiyam, a lot of doctors will soon be getting educated by their patients on Afrezza. that's what will easily occur especially with press. The american diabetes association will have an opinion and those with prick aversion will certainly want to take a puff and accept reality than deny it due to the needle. I'm guessing that we are of like mind; and I appreciate the teachers and mentors amongst us. Be Well. May your Jig line pooch dance continue in a phenomenal way! |
|
|
|
Post by notamnkdmillionaire on Jun 7, 2014 18:16:03 GMT -5
I have a friend who is a respected endocrinologist who evidently was involved with the Pfizer trial. When I sent him info on Mannkind last month he seemed disinterested which really surprised me. He indicated that market reacted poorly to the Pfizer bust and didn't know much about this one. Seemed that he didn't want to discuss it so I wondered if he was not in a position to discuss it. He has traveled and given presentations on diabetes and medications in the past and I wondered if perhaps he knew more than the could tell me. He was aware of who Alfred Mann was and all the past products he was involved in. So perhaps he knows more or is just not interested because of his past involvement in the Pfizer trials. I am am by the way bullish on Mankind. By the words spoken by docs who actually have experience with Afrezza as heard at the Adcom, I'd take your doc friend's reaction as one of indifference not because he knows about Afrezza but because he has been blinded by the failure of Exubera. He is about to have his narrow medical minded world blown up when Afrezza explodes onto the diabetic scene. He'll then have to take his blinders off and learn about Afrezza and see it's not anything like Exubera. But it hits the point the article was making. Many docs have ill formed opinions and won't take the time to educate themselves unless they absolutely have to. |
|
|
|
Post by jpg on Jun 7, 2014 20:20:06 GMT -5
As Chmith said: doctors don't usually know about stuff they can't prescribe and isn't even approved. What would be the point? There is enough to know as is without having to learn what might make it to market. This has nothing to do with narrow minded MDs.
The mental reach for Exubera is normal. That is the only point of comparison of most MDs. This may come as a shick to some but many MDs are not interested in non medical friends giving them medical information... We get bombarded with mostly useless 'medical suggestions' by lay friends. I can for one tell you I have no tolerance to non MD friends or patients telling me of the new great whatever. The way to leverage lay demand for any drug is to have credible medical experts make the same claims. Then it's a no brainer. MDs will prescribe what patients want and quickly if backed by experts.
I think many endocrinologists will be 'sold' by the dynamics of the product and by the elegance of it's mealtime effect. Once leaders start using it there will be a rush by less informed MDs to follow. The ease of dose prescription, lower hypo's and inhaled aspect will be a big deal for PCP in my opinion. Endocrinologists will obviously see the same advantages obviously but many of the 'scientifically respectable' I know will be more impressed by the dynamics first then the other advantages like inhalation second. There might be a move to put more 'hypo prone' patients and less compliant patients on Afrezza first and when MDs see how well it works the barriers will break down quickly. That is why we need a nimble partner with a well educated sales force.
Imagine when 10's of thousand of MDs start really liking Afrezza; buying shares and telling others to buy shares of this new wonder insulin!
JPG
|
|
|
|
Post by spiro on Jun 7, 2014 20:39:24 GMT -5
JPG, after Afrezza is approved, my doctor better listen to me and start prescribing Afrezza or I'm letting the air out of her tires everyday.
|
|
|
|
Post by bradleysbest on Jun 7, 2014 21:05:56 GMT -5
Once approved by the FDA & partnership is announced standby for the intense marketing that will take place!
|
|
|
|
Post by MnkdMainer (MM) on Jun 10, 2014 5:23:33 GMT -5
"Imagine when 10's of thousand of MDs start really liking Afrezza; buying shares and telling others to buy shares of this new wonder insulin."
This makes me think of the performance of Gilead (GILD) over the last 15 years: 12,000%. That's why I'm invested in this stock. I would like to think with social media and patient demand, Afrezza will sell itself, but that may be wishful thinking.
|
|
|
|
Post by 4Balance on Jun 10, 2014 11:56:39 GMT -5
But one key point of the article was doctor's ignorance of diabetes--the disease itself. Is it even credible that an endo would not know the difference between T1 and T2...?? If so, this is shocking.
Is it more likely that he had misread the chart...thinking it was T2, which is far more common?
|
|
|
|
Post by jpg on Jun 12, 2014 21:30:36 GMT -5
But one key point of the article was doctor's ignorance of diabetes--the disease itself. Is it even credible that an endo would not know the difference between T1 and T2...?? If so, this is shocking. Is it more likely that he had misread the chart...thinking it was T2, which is far more common? Doctors aren't perfect (hard to admit...) but all endos (and by far the vast majority of any MDs who treat patients with diabetes) know the difference between a T1 and a T2... If an endo doesn't he or she simply has fake credentials. If a PCP doesn't: get another MD... JPG |
|
|
|
Post by lynn on Jun 12, 2014 23:14:50 GMT -5
I tell everyone about Mannkind ! Grant it I work in a specialty unit but , have yet to meet one Doc who's heard of Afrezza , let alone had any interest in investing in it . Ironically , it's a bunch of Nurses who've invested  I kinda can't wait til the day when I get to say ... Hey Doc , remember that stock I told you about ? Well now it's trading at $X my number is high as should this succeed to reach it's potential , I plan on riding it thru to see the Techosphere platform developed & marketed , ect . . I realize that'll take a while , but I'm in no hurry This is probably something worth being patient for , assuming I get the chance to hold my shares with out Buyout or CRL , knock on wood & I mean no disrespect to Docs whatsoever, but it seems to attract a personality ( there's always exceptions:)) where it's hard to think outside the box .. & they are probably inundated w/ info about new tx therapies , drugs ect .. With social media , this will go viral , the drug will market itself ( but obviously needs ideal partner ).In fact , I'm not changing my FB profile pic ( which is same pic I have here) until great news is announced GLTA:) Lynn |
|
I kinda can't wait til the day when I get to say ... Hey Doc , remember that stock I told you about ? Well now it's trading at $X